H.H. Fiebig
- Toxicology top 5%
- Bioactive Compounds and Antitumor Agents 3
- Oncology top 10%
- Cancer Treatment and Pharmacology 6
- Metal complexes synthesis and properties 5
- HER2/EGFR in Cancer Research 4
- Organic Chemistry top 10%
- Synthesis and biological activity 4
-
- Cancer therapeutics and mechanisms 7
-
- Monoclonal and Polyclonal Antibodies Research 6
- Radiopharmaceutical Chemistry and Applications 3
- Co-authors
- Hans R. HendriksMarkus DreesLloyd R. KèllandØystein FodstadSP LangdonDan BergerW. A. DenglerRosanna Supino
- Cited by
- ToxicologyOncologyOrganic Chemistry
- Journals
- European Journal of Cancer (12 papers)Annals of Oncology (2 papers)Scandinavian Journal of Immunology (1 paper)
- Partner nations
- GermanyNetherlandsUnited States
In The Last Decade
H.H. Fiebig
41 papers receiving 858 citations
Peers
Comparison fields: 5 of 80
- Toxicology 61
- Oncology 440
- Organic Chemistry 273
- Cancer Research 92
- Molecular Biology 387
Countries citing papers authored by H.H. Fiebig
This map shows the geographic impact of H.H. Fiebig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H.H. Fiebig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H.H. Fiebig more than expected).
Fields of papers citing papers by H.H. Fiebig
This network shows the impact of papers produced by H.H. Fiebig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H.H. Fiebig. The network helps show where H.H. Fiebig may publish in the future.
Co-authorship network
The 25 scholars most cited alongside H.H. Fiebig, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2005 | 71 | |
| 2 | 1998 | 15 | |
| 3 | 1998 | 62 | |
| 4 | 1998 | 27 | |
| 5 | 1996 | 3 | |
| 6 | 1996 | 14 | |
| 7 | 1996 | 7 | |
| 8 | 1995 | 21 | |
| 9 | 1995 | 2 | |
| 10 | 1994 | 13 | |
| 11 | 1993 | 89 | |
| 12 | Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study. | 1992 | 74 |
| 13 | 1992 | 25 | |
| 14 | 1992 | 11 | |
| 15 | 1988 | 24 | |
| 16 | 1988 | 1 | |
| 17 | 1984 | 3 | |
| 18 | 1984 | 18 | |
| 19 | [Regulations of IgM immune response. IV. Effect of the hapten: carrier ratio and the nature of the carrier on the intrinsic and functional affinity of carp DNP-antibodies]. | 1979 | 1 |
| 20 | [Regulation of the IgM immune response. I. Changes in the affinity of carp anti-DNP-antibodies during immunization depending on the antigen dose]. | 1977 | 3 |
About H.H. Fiebig
H.H. Fiebig is a scholar working on Toxicology, Oncology, Biophysics, Biotechnology and Radiology, Nuclear Medicine and Imaging, having authored 41 papers that have together received 883 indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (7 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Cancer Treatment and Pharmacology (6 papers), Metal complexes synthesis and properties (5 papers), Synthesis and biological activity (4 papers), HER2/EGFR in Cancer Research (4 papers), Bioactive Compounds and Antitumor Agents (3 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). The work is most often cited by research in Toxicology (61 citations), Oncology (440 citations), Organic Chemistry (273 citations), Cancer Research (92 citations) and Molecular Biology (387 citations). H.H. Fiebig has collaborated with scholars based in Germany, Netherlands and United States. Frequent co-authors include Hans R. Hendriks, Markus Drees, Lloyd R. Kèlland, Øystein Fodstad, SP Langdon, Dan Berger, W. A. Dengler, Rosanna Supino, Nicholas P. Farrell and Roberto Di Domenico. Their work appears in journals such as European Journal of Cancer, Annals of Oncology, Scandinavian Journal of Immunology, British Journal of Cancer and Investigational New Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.